Welcome to our dedicated page for Penumbra SEC filings (Ticker: PEN), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Penumbra, Inc. filings document the regulatory record for a NYSE-listed medical-device company focused on thrombectomy technologies for stroke, pulmonary embolism, venous thromboembolism, and acute limb ischemia. Form 8-K reports cover operating results, material-event disclosures, material agreements, capital-structure matters, and clinical or regulatory updates involving its thrombectomy portfolio.
Proxy materials describe shareholder voting matters, governance practices, compensation arrangements, and capital-structure proposals. The filing record also includes disclosures on risk factors, financial condition, executive appointments and compensatory arrangements, and the company's common stock registered under the symbol PEN on the New York Stock Exchange.
Form 144 Notice of Proposed Sale filed by Adam Elsesser of Penumbra indicates planned sale of 15,890 shares of common stock with an aggregate market value of $4,026,584.79. The sale is scheduled for June 25, 2025, through Morgan Stanley Smith Barney LLC on the NYSE.
The shares were acquired through a stock option exercise on June 25, 2025, with cash payment. The filing reveals significant recent selling activity by Elsesser over the past 3 months:
- June 11, 2025: 15,910 shares for $4.04M
- May 28, 2025: 16,300 shares for $4.37M
- May 14, 2025: 16,600 shares for $4.95M
- May 7, 2025: 16,650 shares for $4.82M
- April 16, 2025: 16,560 shares for $4.54M
- April 2, 2025: 16,565 shares for $4.51M
Total shares outstanding: 38,725,940. The seller affirms no knowledge of undisclosed material adverse information regarding Penumbra's operations.
Penumbra Director Bridget O'Rourke reported a Form 4 filing disclosing the sale of 50 shares of common stock at a price of $259.78 per share on June 16, 2025. The transaction was executed under a pre-established Rule 10b5-1 trading plan, which provides a safe harbor from insider trading allegations.
Following the transaction, O'Rourke maintains beneficial ownership of 5,373 shares held directly, with a portion subject to vesting restrictions. The filing was submitted on June 28, 2025, within the required reporting timeframe.
- Transaction Type: Sale of Common Stock
- Total Transaction Value: $12,989
- Ownership Form: Direct
- Role: Director